Trump announces trade deal with EU following months of negotiations
Berenberg initiated coverage on Swiss pharmaceutical contract manufacturer Bachem Holding AG (SIX:BANB) with a Buy rating and a price target of CHF73.00, representing a potential 35% upside from current levels.
The research firm cited Bachem’s position as a leading contract development and manufacturing organization (CDMO) specializing in chemical synthesis for peptides and oligonucleotides-based active pharmaceutical ingredients (APIs).
Bachem provides comprehensive services to pharmaceutical and biotechnology customers throughout the drug development lifecycle, from early development stages through regulatory approval and commercialization.
Berenberg highlighted growth opportunities in the synthetic peptide CDMO market, noting the success of peptides generally and GLP-1s specifically, along with expansion into new indications and formulations that are driving industry pipeline growth for larger patient populations requiring higher peptide volumes.
The increasing complexity of these molecules creates demand for chemical synthesis specialists, with Berenberg estimating the market will grow by more than 10% compound annual growth rate from 2025 to 2030.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.